iPS Cells & Regenerative Medicine– category –
-
Advanced CAR-T/NK Therapies for Solid Tumors: iPSC-Derived CAR-NK Cells Show Promise in Efficacy and Safety
Oncodaily Global Overview In solid tumor treatment, IL-15 armed GPC3 CAR-T cells demonstrated promising early data, with cytokine release syndrome (CRS) managed by an inducible caspase-9 switch. Notably, iPSC-derived IL-15 incorporated C... -
Future of CAR T-Cell Therapy: Multi-Target, Off-the-Shelf Strategies and Manufacturing Innovation to Overcome Solid Tumors
Frontiers in Molecular Medicine Global Overview While CAR T-cell therapy revolutionized hematologic cancer treatment, challenges persist in solid tumors, including antigen heterogeneity, immunosuppressive tumor microenvironments, and poo... -
Converging 3D Bioprinting and Organoids: A Novel Approach Revolutionizing Disease Modeling and Regenerative Medicine
Oxford Academic (Regenerative Biomaterials) Global Overview The convergence of 3D bioprinting and organoid technology presents a new paradigm poised to revolutionize disease modeling, drug screening, and regenerative medicine. 3D bioprin... -
Understanding Regenerative Medicine: Distinguishing PMDA-Approved Treatments from Research in Japan
GINZA YR CLINIC Japan Overview Regenerative medicine, encompassing cell therapies, stem cell research, and tissue engineering, aims to restore damaged tissues and organs. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) is... -
Allogene’s Off-the-Shelf CAR T Cema-Cel Secures FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
OncLive USA Overview Allogene Therapeutics' off-the-shelf anti-CD19 CAR T-cell therapy, cemacabtagene ansegedleucel (cema-cel), received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for first-line consoli... -
FDA Regenerative Medicine Approvals Accelerate: Record 8 Approvals in 2024, RMAT Designations Signal Continued Momentum
Pharmaceutical Technology USA Overview U.S. FDA approvals for regenerative medicine products have accelerated significantly, reaching a record eight approvals in 2024. The surge in Regenerative Medicine Advanced Therapy (RMAT) designatio... -
Allogene’s Off-the-Shelf CAR T, Cema-Cel, Earns FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
Allogene Therapeutics, Inc. USA Overview Allogene Therapeutics has secured FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its investigational allogeneic CAR T-cell therapy, cemacabtagene ansegedleucel (... -
iPSC-Derived Cell Therapy Pipeline Expands: Hopstem Leads Chinese Market with Neurological and Immunological Disease Applications
BioInformant USA Overview The iPSC-derived cell therapy pipeline is rapidly expanding from disease modeling to clinical applications across cardiovascular, neurological, metabolic, ocular, and oncological diseases. Hopstem Biotechnology ... -
FDA Clarifies Regenerative Medicine Regulations: Strategic Use of RMAT Designation and HCT/P Classification to Accelerate Development
Global MedTech Expert USA Overview The U.S. FDA has detailed its Regenerative Medicine Advanced Therapy (RMAT) designation, offering a fast-track development framework for cell and gene therapies targeting serious or life-threatening dis... -
iPS Cells & Regenerative Medicine Weekly Report July 26, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report July 26, 2026 (PDF) — Download Weekly Report July 26, 2026 (PDF) — DownloadDownload 🎙 Podcast July 26, 2026 (...
